Top

Published in:

01-05-2012 | Epidemiology

Favorable outcome associated with an IGF-1 ligand signature in breast cancer

Authors: Lina Mu, David Tuck, Dionyssios Katsaros, Lingeng Lu, Vincent Schulz, Sudhir Perincheri, Guido Menato, Luca Scarampi, Lyndsay Harris, Herbert Yu

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Abstract

The insulin-like growth factor (IGF) axis is fundamentally important in cell growth, development and cancer. We used genomic technologies to better characterize the activity of the IGF axis in human breast cancer and to identify predictors of response to IGF targeted therapies. Analysis of the gene expression patterns and pathway analysis in 204 clinically annotated primary breast cancers were performed and compared to levels of mRNA for IGF ligands and receptors. Pathway activation scores were calculated by Pearson correlation (+1, −1). Network analysis was performed using Ingenuity software. IGF-1 ligand levels were strongly negatively correlated (P < 10⁻⁶) with a published IGF-IR activation signature. A signature of high IGF-1 ligand was associated with better prognosis (P = 0.025–1.5 × 10⁻⁸) in several public datasets. Pathway analysis revealed upregulation of pathways associated with breast differentiation (adipocyte growth factors, PPAR-gamma) and down-regulation of proliferation pathways (AKT/MAPK) in the IGF-1 ligand high group. Of note, the IGF-1 ligand signature was anti-correlated with IGFIR receptor levels (P = 0.07). In conclusion, a breast tumor-derived signature of high IGF-1 ligand is associated with favorable outcome, in contrast to a previously reported IGF-IR activation signature. The prognostic value of the IGF-I ligand signature is validated in three independent datasets. These signatures should be applied in study of IGF1-R targeted therapy.

Available only for authorised users

Bonneterre J, Peyrat JP, Beuscart R, Demaille A (1990) Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50(21):6931–6935PubMed

Blum G, Gazit A, Levitzki A (2003) Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278(42):40442–40454PubMedCrossRef

Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63(24):8912–8921PubMed

Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505–518PubMedCrossRef

Surmacz E (2003) Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene. 22(42):6589–6597PubMedCrossRef

Baserga R, Glazer PM, Turner BC, Haffty BG, Narayanan L, Yuan J et al (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57(15):3079–3083PubMed

Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279(6):5017–5024PubMedCrossRef

Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG et al (2008) Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26(25):4078–4085PubMedCrossRef

Mu L, Katsaros D, Wiley A, Lu L, de la Longrais I, Smith S et al (2008) Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res Treat [Internet] (cited 2008 Sep 27). http://www.ncbi.nlm.nih.gov/pubmed/18481170

10.

Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80PubMedCrossRef

11.

Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24(13):1547–1548PubMedCrossRef

12.

Lin SM, Du P, Huber W, Kibbe WA (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36(2):e11PubMedCrossRef

13.

Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3(3)

14.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 57(1):289–300

15.

The R Project for Statistical Computing. http://www.r-project.org)

16.

Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679PubMed

17.

van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AAM, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009PubMedCrossRef

18.

Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6):529–541PubMedCrossRef

19.

Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167PubMedCrossRef

20.

Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA). http://www.ingenuity.com

21.

Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58(6):1159–1164PubMed

22.

Kim H, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X et al (2007) Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-{kappa}B and snail. Mol Cell Biol 27(8):3165–3175PubMedCrossRef

23.

Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R et al (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58(15):3353–3361PubMed

24.

Zhang X, Kamaraju S, Hakuno F, Kabuta T, Takahashi S, Sachdev D et al (2004) Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 83(2):161–170PubMedCrossRef

25.

Shin A, Ren Z, Shu X, Cai Q, Gao Y, Zheng W (2007) Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat 105(1):55–61PubMedCrossRef

26.

Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama KI, Endoh H et al (2000) Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells. 5(8):593–601PubMedCrossRef

27.

Huynh H, Nickerson T, Pollak M, Yang X (1996) Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 2(12):2037–2042PubMed

28.

Lee AV, Weng CN, Jackson JG, Yee D (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152(1):39–47PubMedCrossRef

29.

Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK et al (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13(5):787–796PubMedCrossRef

30.

Decensi A, Robertson C, Ballardini B, Paggi D, Guerrieri-Gonzaga A, Bonanni B et al (1999) Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer 35(4):596–600PubMedCrossRef

31.

Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183(4):412–417PubMedCrossRef

32.

Ye J, Liang S, Guo N, Li S, Wu AM, Giannini S et al (2003) Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 35(11–12):836–842PubMed

33.

Ciarmatori S, Kiepe D, Haarmann A, Huegel U, Tönshoff B (2007) Signaling mechanisms leading to regulation of proliferation and differentiation of the mesenchymal chondrogenic cell line RCJ3.1C5.18 in response to IGF-I. J Mol Endocrinol 38(4):493–508PubMedCrossRef

34.

Ewton DZ, Kansra S, Lim S, Friedman E (2002) Insulin-like growth factor-I has a biphasic effect on colon carcinoma cells through transient inactivation of forkhead1, initially mitogenic, then mediating growth arrest and differentiation. Int J Cancer 98(5):665–673PubMedCrossRef

35.

Rosenthal SM, Cheng ZQ (1995) Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci USA 92(22):10307–10311PubMedCrossRef

36.

Wei Y, Chen Y, Li D, Gu R, Wang W (2004) Dual effect of insulin-like growth factor on the apical 70-pS K channel in the thick ascending limb of rat kidney. Am J Physiol Cell Physiol 286(6):C1258–C1263PubMedCrossRef

37.

Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C et al (1996) The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38(1):57–66PubMedCrossRef

38.

Marte BM, Jeschke M, Graus-Porta D, Taverna D, Hofer P, Groner B et al (1995) Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Mol Endocrinol 9(1):14–23PubMedCrossRef

39.

Nagashima T, Shimodaira H, Ide K, Nakakuki T, Tani Y, Takahashi K et al (2007) Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. J Biol Chem 282(6):4045–4056PubMedCrossRef

40.

Staebler A, Sommers C, Mueller SC, Byers S, Thompson EW, Lupu R (1994) Modulation of breast cancer progression and differentiation by the gp30/heregulin [correction of neregulin]. Breast Cancer Res Treat 31(2–3):175–182PubMedCrossRef

41.

Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC (1999) The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5(11):3653–3660PubMed

42.

Hallstrom TC, Mori S, Nevins JR (2008) An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13(1):11–22PubMedCrossRef

43.

Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al (1998) Terminal differentiation of human breast cancer through PPAR[gamma]. Mol Cell 1(3):465–470PubMedCrossRef

44.

Massagué J (2008) TGF[beta] in cancer. Cell 134(2):215–230PubMedCrossRef

45.

Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E (1996) TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10(19):2462–2477PubMedCrossRef

46.

Danielpour D, Song K (2006) Cross-talk between IGF-I and TGF-[beta] signaling pathways. Cytokine Growth Factor Rev 17(1–2):59–74PubMedCrossRef

47.

Jassem J, Langer CL, Karp DD, Mok T, Novello S, Park K, Strausz J, Benner RJ, Green S, Gualberto A (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Annual Meeting 2010. Abstract #7500, Chicago

Title: Favorable outcome associated with an IGF-1 ligand signature in breast cancer
Authors: Lina Mu
David Tuck
Dionyssios Katsaros
Lingeng Lu
Vincent Schulz
Sudhir Perincheri
Guido Menato
Luca Scarampi
Lyndsay Harris
Herbert Yu
Publication date: 01-05-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-1952-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

Black–white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US

Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus

Not so fast: the use of incomplete data to devalue the role of mammography screening

Genetic heterogeneity in HER2 testing may influence therapy eligibility

Keynote webinar | Spotlight on antibody–drug conjugates in cancer